These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 9219045)

  • 1. Milnacipran, a new serotonin and noradrenaline reuptake inhibitor: an overview of its antidepressant activity and clinical tolerability.
    Puech A; Montgomery SA; Prost JF; Solles A; Briley M
    Int Clin Psychopharmacol; 1997 Mar; 12(2):99-108. PubMed ID: 9219045
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of Milnacipran Treatment on Ventricular Lactate in Fibromyalgia: A Randomized, Double-Blind, Placebo-Controlled Trial.
    Natelson BH; Vu D; Mao X; Weiduschat N; Togo F; Lange G; Blate M; Kang G; Coplan JD; Shungu DC
    J Pain; 2015 Nov; 16(11):1211-9. PubMed ID: 26335989
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of Milnacipran on Plasma Level of Vascular Endothelial Growth Factor in Major Depression.
    Yoshimura R; Ikenouchi A; Okamoto N
    Psychopharmacol Bull; 2022 Oct; 52(4):106-108. PubMed ID: 36339278
    [No Abstract]   [Full Text] [Related]  

  • 4. Milnacipran: a selective serotonin and norepinephrine dual reuptake inhibitor for the management of fibromyalgia.
    Palmer RH; Periclou A; Banerjee P
    Ther Adv Musculoskelet Dis; 2010 Aug; 2(4):201-20. PubMed ID: 22870448
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chirality of antidepressive drugs: an overview of stereoselectivity.
    Vashistha VK; Sethi S; Tyagi I; Das DK
    Asian Biomed (Res Rev News); 2022 Apr; 16(2):55-69. PubMed ID: 37551287
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Paroxetine versus other anti-depressive agents for depression.
    Cipriani A; Furukawa TA; Veronese A; Watanabe N; Churchill R; McGuire H; Barbui C
    Cochrane Database Syst Rev; 2007; (2):. PubMed ID: 25267892
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Venlafaxine versus other anti-depressive agents for depression.
    Cipriani A; Signoretti A; Furukawa TA; Churchill R; Tomelleri S; Omori IM; McGuire H; Barbui C
    Cochrane Database Syst Rev; 2007; (2):. PubMed ID: 25267891
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evidence-based, pharmacological treatment guideline for depression in Korea, revised edition.
    Won E; Park SC; Han KM; Sung SH; Lee HY; Paik JW; Jeon HJ; Lee MS; Shim SH; Ko YH; Lee KJ; Han C; Ham BJ; Choi J; Hwang TY; Oh KS; Hahn SW; Park YC; Lee MS;
    J Korean Med Sci; 2014 Apr; 29(4):468-84. PubMed ID: 24753693
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vitamin B12 supplementation in treating major depressive disorder: a randomized controlled trial.
    Syed EU; Wasay M; Awan S
    Open Neurol J; 2013; 7():44-8. PubMed ID: 24339839
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Double-blind, comparative study of milnacipran and paroxetine in Japanese patients with major depression.
    Kamijima K; Hashimoto S; Nagayoshi E; Koyama T
    Neuropsychiatr Dis Treat; 2013; 9():555-65. PubMed ID: 23650446
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mirtazapine versus other antidepressive agents for depression.
    Watanabe N; Omori IM; Nakagawa A; Cipriani A; Barbui C; Churchill R; Furukawa TA
    Cochrane Database Syst Rev; 2011 Dec; (12):CD006528. PubMed ID: 22161405
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improvement of the noradrenergic symptom cluster following treatment with milnacipran.
    Kasper S; Meshkat D; Kutzelnigg A
    Neuropsychiatr Dis Treat; 2011; 7(Suppl 1):21-7. PubMed ID: 21750625
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fluvoxamine versus other anti-depressive agents for depression.
    Omori IM; Watanabe N; Nakagawa A; Cipriani A; Barbui C; McGuire H; Churchill R; Furukawa TA
    Cochrane Database Syst Rev; 2010 Mar; (3):CD006114. PubMed ID: 20238342
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of milnacipran in patients suffering from poststroke depression.
    Arora H; Kaur R
    Indian J Psychiatry; 2009; 51(3):228. PubMed ID: 19881058
    [No Abstract]   [Full Text] [Related]  

  • 15. Milnacipran versus other antidepressive agents for depression.
    Nakagawa A; Watanabe N; Omori IM; Barbui C; Cipriani A; McGuire H; Churchill R; Furukawa TA
    Cochrane Database Syst Rev; 2009 Jul; 2009(3):CD006529. PubMed ID: 19588396
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Escitalopram versus other antidepressive agents for depression.
    Cipriani A; Santilli C; Furukawa TA; Signoretti A; Nakagawa A; McGuire H; Churchill R; Barbui C
    Cochrane Database Syst Rev; 2009 Apr; (2):CD006532. PubMed ID: 19370639
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and tolerability of milnacipran in the treatment of major depression in comparison with other antidepressants : a systematic review and meta-analysis.
    Nakagawa A; Watanabe N; Omori IM; Barbui C; Cipriani A; McGuire H; Churchill R; Furukawa TA;
    CNS Drugs; 2008; 22(7):587-602. PubMed ID: 18547127
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Remission rates with milnacipran 100 mg/day and 150 mg/day in the long-term treatment of major depression.
    Okumura K; Furukawa TA
    Clin Drug Investig; 2006; 26(3):135-42. PubMed ID: 17163244
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chronic treatment with milnacipran reverses the impairment of synaptic plasticity induced by conditioned fear stress.
    Matsumoto M; Tachibana K; Togashi H; Tahara K; Kojima T; Yamaguchi T; Yoshioka M
    Psychopharmacology (Berl); 2005 May; 179(3):606-12. PubMed ID: 15619117
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.